



EMA/371512/2017 Rev.1

**Update of 19 October 2017:**

The shortage affecting Cinryze has been resolved and the below information and recommendations which were issued during the shortage no longer apply.

31 October 2017

**Shortage of Cinryze (C1 inhibitor, human)  
powder and solvent for intravenous injection**

<b>Indication</b>	<p>Cinryze is a medicine used to treat treat angioedema (swelling) attacks in adults and adolescents aged 12 to 17 years with hereditary angioedema.</p> <p>Cinryze is also used for the prevention of angioedema attacks that can be triggered by medical, dental or surgical procedures.</p> <p>Cinryze is also used for routine prevention in patients who have severe and frequent angioedema attacks for which prevention with oral medicines is not adequate or in patients whose attacks are not adequately treated.</p>
<b>Reason for shortage</b>	<p>The manufacturer is currently facing an increased demand for Cinryze which outweighs current production capabilities. This may result in a temporary supply shortage while the manufacturer is adjusting production capacity.</p>
<b>Member States affected<sup>1</sup></b>	<p>The EU Member States that may be impacted by a potential shortage are: Austria, Denmark, France, Germany, Ireland, Italy, Spain, Sweden, United Kingdom, as well as Iceland and Norway.</p>
<b>Information for healthcare professionals</b>	<ul style="list-style-type: none"><li>• An increased demand for Cinryze may result in a temporary supply shortage in the next month while the manufacturer is adjusting production capacity.</li><li>• Healthcare professionals have been informed in writing about the potential supply problem.</li><li>• In order to manage existing stocks, prescribers should consider alternative treatment options for patients who</li></ul>

<sup>1</sup> This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the [national competent authority](#).



## Shortage of Cinryze (C1 inhibitor, human) powder and solvent for intravenous injection

	<p>require treatment and pre-procedure prevention of angioedema attacks.</p> <ul style="list-style-type: none"><li>• When used for routine prevention of angioedema attacks patients may continue to receive Cinryze.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li></ul>
<b>Information for patients</b>	<ul style="list-style-type: none"><li>• An increased demand for Cinryze may result in a temporary supply shortage in the next month while the manufacturer is adjusting production capacity.</li><li>• To manage stocks efficiently, doctors will consider alternative treatment when using Cinryze for treatment of angioedema attacks and prevention before medical, dental or surgical procedures.</li><li>• When used for routine prevention of angioedema attacks patients may continue to receive Cinryze.</li><li>• Patients who have any questions should speak to their doctor or pharmacist.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li></ul>